| Literature DB >> 27816060 |
Damien Contou1,2, Damien Roux3, Sébastien Jochmans4, Rémi Coudroy5, Emmanuel Guérot6, David Grimaldi7, Sylvie Ricome8, Eric Maury9, Gaëtan Plantefève10, Julien Mayaux11, Armand Mekontso Dessap12,13, Christian Brun-Buisson12,13, Nicolas de Prost12,13.
Abstract
BACKGROUND: The lack of a patent source of infection after 24 hours of management of shock considered septic is a common and disturbing scenario. We aimed to determine the prevalence and the causes of shock with no diagnosis 24 hours after its onset, and to compare the outcomes of patients with early-confirmed septic shock to those of others.Entities:
Keywords: Acute mesenteric ischemia; Intensive care; Sepsis; Sepsis mimickers; Septic shock
Mesh:
Year: 2016 PMID: 27816060 PMCID: PMC5097846 DOI: 10.1186/s13054-016-1537-5
Source DB: PubMed Journal: Crit Care ISSN: 1364-8535 Impact factor: 9.097
Fig. 1Flow chart. *Shock with no source of infection nor microbiological documentation at 24 h of study inclusion
Baseline characteristics of patients admitted to the ICU with suspected septic shock (n = 508) and comparison between patients with early-confirmed septic shocks (EC-SS) and other patients (non EC-SS)
| All patients ( | EC-SS ( | Non EC-SS ( |
| |
|---|---|---|---|---|
| Age and gender | ||||
| Age, years | 68 (59–79) | 67 (58–80) | 68 (61–78) | 0.81 |
| Male gender | 297 (58) | 219 (59) | 78 (58) | >0.99 |
| Comorbidities | ||||
| Chronic respiratory disease | 21 (4) | 17 (5) | 4 (3) | 0.44 |
| Chronic heart failure | 34 (7) | 22 (6) | 12 (9) | 0.22 |
| Chronic kidney disease | 46 (9) | 33 (9) | 13 (10) | 0.76 |
| Cirrhosis | 49 (10) | 35 (9) | 14 (10) | 0.71 |
| Recent malignant hemopathy | 34 (7) | 27 (7) | 7 (5) | 0.43 |
| Recent cancer | 63 (12) | 43 (11) | 20 (15) | 0.30 |
| Diabetes mellitus | 132 (26) | 87 (23) | 45 (34) | 0.019 |
| HIV infection | 17 (3) | 11 (3) | 6 (4) | 0.40 |
| Obesity | 71 (14) | 54 (14) | 17 (13) | 0.62 |
| Cerebrovascular disease | 55 (11) | 37 (10) | 18 (13) | 0.26 |
| Immunosuppressive therapy | 54 (11) | 41 (11) | 13 (10) | 0.68 |
| Immunosuppression statusa | 132 (26) | 95 (25) | 37 (28) | 0.62 |
| No coexisting comorbid conditions | 154 (30) | 119 (32) | 35 (26) | 0.22 |
| Clinical data within 24 h of inclusion and antibiotic therapy | ||||
| Maximal temperature, °C | 38.2 (37.3–39.0) | 38.4 (37.4 − 39.1) | 37.9 (36.9 − 38.6) | <0.0001 |
| Minimal temperature, °C | 36.1 (35.2–37.0) | 36.2 (35.4–37.0) | 36.0 (34.6–36.8) | 0.006 |
| Glasgow Coma Scale | 14 (11–15) | 15 (12–15) | 13 (9–15) | 0.002 |
| SAPS2 | 58 (47–73) | 58 (45–72) | 59 (50–75) | 0.34 |
| Delay admission-inclusion, hours | 1 (0–6) | 2 (0–7) | 1 (0–4) | 0.33 |
| Delay inclusion -ATB1, hours | 0 (0–1) | 0 (0–1) | 0 (0–1) | 0.28 |
| Delay inclusion -ATB2, hours | 0 (0–2) | 0 (0–2) | 0 (0–2) | 0.59 |
| Number of ATB administered at 3 h | 2 (1–2) | 2 (1–2) | 2 (1–2) | 0.09 |
| Number of ATB administered at 24 h | 2 (2–3) | 2 (2–3) | 2 (1–3) | 0.050 |
| Biological data within 24 h of inclusion | ||||
| Leukocyte count, 103.mm−3 | 16.5 (9.9–24.6) | 17.1 (9.8–24.9) | 15.9 (9.9–23.0) | 0.62 |
| Platelets count, 103/mm−3 | 156 (85–243) | 156 (81–45) | 155 (92–236) | 0.72 |
| C-reactive protein, mg/Lb | 166 (87 − 265) | 178 (110 − 288) | 108 (48–179) | <0.0001 |
| Procalcitonin, ng/mLc | 7.6 (1.3–37.9) | 19.6 (3.7–56.5) | 1.6 (0.7–7.8) | <0.0001 |
| Serum urea, mmol/L | 14.0 (8.7–21.7) | 13.6 (8.7–20.0) | 16.0 (9.1–24.0) | 0.16 |
| Serum creatinine, μmoL/L | 187 (114–296) | 187 (115–275) | 198 (107–347) | 0.13 |
| Prothrombin time, % | 58 (41–72) | 58 (42–72) | 56 (38–72) | 0.72 |
| Arterial lactate, mmol/L | 3.5 (2.0–7.0) | 3.4 (2.0–6.1) | 3.6 (2.0–10.0) | 0.13 |
Categorical variables are expressed as number (%) and continuous variables as median (IQR 25–75). aImmunosuppression status includes patients with HIV or malignant hemopathy or recent cancer, or under immunosuppressive therapy. bValue available for 248 patients. cValue available for 128 patients. ATB antibiotic therapy, h hour, HIV human immunodeficiency virus, SAPS2 Simplified Acute Physiology Score, WBC white blood count
Causes of shock in the 134 patients with non-early-confirmed septic shock (non EC-SS, i.e., patients with shock but no source of infection or microbiological documentation at 24 h after onset of shock)
| Causes | Number (%) |
|---|---|
| Late-confirmed septic shock (LC-SS), | 37/134 (28) |
| Pleuro-pulmonary | 13/37 (35) |
| Urinary tract | 6/37 (16) |
| Abdomen | 4/37 (11) |
| Liver and biliary tract | 4/37 (11) |
| Primary bloodstream infection | 4/37 (11) |
| Skin and soft tissues | 2/37 (5) |
| Endocarditis | 1/37 (3) |
| Bone-joint | 1/37 (3) |
| Central nervous system | 1/37 (3) |
| Endovascular stent infection | 1/37 (3) |
| Septic shock mimickers (SSM), | 59/134 (44) |
| Adverse effects of drugs | 22/59 (37) |
| Metformin | 10 |
| Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers | 4 |
| β-blockers | 2 |
| Propofol | 2 |
| Othersa | 4 |
| Vascular | 12/59 (20) |
| Acute mesenteric ischemia | 12 |
| Arterial | 10 |
| Venous | 2 |
| Malignancies | 9/59 (15) |
| Lymphoma | 3 |
| Solid tumor (including one Marastic endocarditis) | 4 |
| Tumor lysis syndrome | 2 |
| Inflammatory diseases | 5/59 (8) |
| Hemophagocytic lymphohistiocytosis | 2 |
| Drug rash with eosinophilia and systemic symptoms | 1 |
| Catastrophic antiphospholipid syndrome | 1 |
| Cholesterol embolization syndrome | 1 |
| Metabolic disorders | 4/59 (7) |
| Acute adrenal insufficiency | 2 |
| Diabetic ketoacidosis | 2 |
| Acute pancreatitis | 4/59 (7) |
| Miscellaneous | 3/59 (5) |
| Abdominal compartment syndrome | 1 |
| Air embolismb | 1 |
| “Reventilation” syndrome | 1 |
| Shock of unknown origin (SUO), | 38/134 (28 %) |
Categorical variables are expressed as n (%). aIncluding neuroleptic (n = 1), lithium (n = 1), intravenous immunoglobulins (n = 1), sorafenib (n = 1). bAir embolism was clinically suspected and confirmed by autopsy
Organ support and outcomes in patients admitted to the ICU with suspected septic shock (n = 508) and comparison between patients with early-confirmed septic shock (EC-SS) or non-early confirmed septic shock (Non EC-SS)
| All patients ( | EC-SS ( | Non EC-SS ( |
| |
|---|---|---|---|---|
| Tracheal intubation | 397 (78) | 294 (79) | 103 (77) | 0.67 |
| ARDS | 167 (33) | 143 (38) | 24 (18) | <0.0001 |
| Renal replacement therapy | 145 (28) | 95 (25) | 50 (37) | 0.009 |
| Steroids for septic shocka | 197 (39) | 143 (38) | 54 (40) | 0.67 |
| ECMO | 8 (2) | 5 (1) | 3 (2) | 0.44 |
| Duration of tracheal intubation, days | 4 (1 − 9) | 4 (1 − 9) | 4 (0 − 6) | 0.19 |
| Duration of vasopressors support, days | 3 (2 − 5) | 3 (2 − 5) | 3 (2 − 6) | 0.55 |
| Duration of ICU stay, days | 7 (4 − 14) | 7 (4 − 24) | 7 (4 − 21) | 0.69 |
| ICU mortality | 188 (37) | 139 (37) | 49 (37) | 0.90 |
| Follow-up duration, days | 29 (7 − 96) | 30 (8 − 91) | 25 (6 − 113) | 0.75 |
| Mortality over the follow-up period | 232 (46) | 166 (44) | 66 (49) | 0.33 |
Categorical variables are expressed as n (%) and continuous variables as median (IQR 25–75). aIncludes eight patients receiving either steroids or placebo because of clinical trial enrolment.
ARDS acute respiratory distress syndrome, ECMO extra-corporeal membrane oxygenation, ICU Intensive Care Unit
Fig. 2Kaplan–Meier plot of the probability of survival from inclusion to day 60 in patients with early-confirmed septic shock (EC-SS, blue curve) and other patients (Non EC-SS, red curve)
Factors associated with day-60 mortality in univariable and multivariable Cox models
| Variables | Univariable analysis | Multivariable analysisa | ||
|---|---|---|---|---|
| HR (95 % CI) |
| HR (95 % CI) |
| |
| Categorization of shock | ||||
| EC-SS | 1 | - | - | |
| Non EC-SS | 0.87 (0.65–1.16) | 0.34 | ||
| Cirrhosis | ||||
| No | 1 | 1 | ||
| Yes | 2.04 (1.42–2.93) | <0.0001 | 2.45 (1.63–3.69) | <0.0001 |
| Cancer | ||||
| No | 1 | 1 | ||
| Yes | 1.62 (1.15–2.28) | 0.006 | 1.91 (1.32–2.75) | <0.001 |
| Chronic respiratory failure | ||||
| No | 1 | 1 | ||
| Yes | 2.16 (1.30–3.59) | 0.003 | 2.45 (1.41–4.26) | 0.002 |
| Age >68 years | ||||
| No | 1 | 1 | ||
| Yes | 1.47 (1.14–1.91) | <0.0001 | 1.73 (1.30–2.30) | <0.0001 |
| SAPS2 > 58 | ||||
| No | 1 | 1 | ||
| Yes | 3.01 (2.28–3.96) | <0.0001 | 1.94 (1.43–2.64) | <0.0001 |
| PT ratio <50% | ||||
| No | 1 | 1 | ||
| Yes | 1.96 (1.50–2.55) | <0.0001 | 1.41 (1.05–1.91) | 0.024 |
| Mechanical ventilation | ||||
| No | 1 | 1 | ||
| Yes | 3.65 (2.33–5.72) | <0.0001 | 2.53 (1.57–4.09) | <0.0001 |
| Lactate, per point in mmol/L | 1.09 (1.07–1.11) | <0.0001 | 1.06 (1.04–1.09) | <0.0001 |
Patients were categorized as having early-confirmed (i.e., within 24 h of vasopressor initiation) septic shock (EC-SS) or not (non EC-SS). aAdjusted for center. CI confidence interval, HR hazard ratio, PT prothrombin time, SAPS2 simplified acute physiology score 2